Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas

Chemotherapy

Volumn 50, Issue 3, 2004, Pages 127-132

  Oztop, Ilhan ^a   Yilmaz, Ugur ^a   Yavuzsen, Tugba ^a   Yaren, Arzu ^a   Tarhan, Oktay ^a   Sagol, Ozgul ^a   Coker, Ahmet ^a   Alakavuklar, Mehmet ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

5 fluorouracil; Advanced pancreatic cancer; Gemcitabine

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 3242749729     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077886     Document Type: Article

References (34)

1. Moore M: Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review. Cancer 1996;78:633-638.
2. Oster MW, Gray R, Panasci L, Perry MC: Chemotherapy for advanced pancreatic cancer: A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986;57:29-33.
3. Cullinan S, Moertel CG, Wineand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF: A phase III trial on the therapy of advanced pancreatic carcinoma: Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990;65:2207-2212.
4. Moertel CG: Chemotherapy of gastrointestinal cancer. Clin Gastroenterol 1976;5:777-793.
5. Hansen R, Quebbeman E, Ritch P, Chitambar C, Anderson T: Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: A phase II study. Am J Med Sci 1988;295:91-93.
6. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 1991;9:2128-2133.
7. Ahlgren JD: Chemotherapy for pancreatic carcinoma. Cancer 1996;78(3 suppl):654-663.
8. Casper ES, Green MR, Kelsen DP, Heelen RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2,2P- difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
9. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-105.
10. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Stomiolo AM, Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
11. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Stomiolo AM, Tarassoff PG, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
12. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;14:808-815.
13. Ducreux M, Ychou M, Seitz JF, Bonnay M, et al: Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-ending and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17:2901-2908.
14. Yang TS, Chen JS, Tang R, Chiang JM, Hsieh PS, Yeh CY, Changchien CR: Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: A phase II study. Chemotherapy 2003;49:194-199.
15. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 2000;355:1041-1047.
16. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
17. Oettle H, Riess H: Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 2002;95:912-922.
18. Oettle H, Arning M, Pelzer U, Arnold D, Stroszczynski C, Langrehr J, Reitzig P, Kindler M, Herrenberger J, Musch R, Korsten EW, Huhn D, Riess H: Phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol 2000;11:1267-1272.
19. Louvet C, André T, Hammel P: Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 2001;12:675-679.
20. Gurzler F, Moehler M, Hosch WP, et al: A phase I study of gemcitabine (GEM) in combination with five days 5-fluorouracil (5-FU) and folinic acid (FA) in patients with advanced adenocarcinoma of pancreas or bile duct. Proc Am Soc Clin Oncol 1999;18:A1097.
21. Jovtis S, Marantz A, Almira E, et al: Phase II trial of gemcitabine (GEM), 5-fluorouracil and leucovorin (LV) in advanced pancreatic cancer (APC). Eur J Cancer 1999;35:A586.
22. Castellano D, Paz-Ares L, Pronk L, et al: A phase I/II clinical and pharmacologic study of dose-escalating and dose-sequencing of administration of gemcitabine (G) and folinic acid (FA)/fluorouracil (FU) in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2000;19:A1133.
23. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999;17:585-592.
24. Borner MM, Maurer CA, Friess H, et al: Gemcitabine (GEM) and continuous infusion fluorouracil (CIF): A phase II study in advanced pancreatic cancer (APC). Ann Oncol 1998;9:A241P.
25. Anchisi S, Delaloye B, Petite J, et al: Gemcitabine (Gem) and continuous infusion 5-FU (Cif) is active and well tolerated in advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2000;19:A1280H.
26. Rodriguez-Lescure A, Carrato A, Massuti B, et al: Phase I-II study of gemcitabine (GEM) and weekly-48-hour continuous infusion (CI) of high-dose 5-fluorouracil (5-FU) in advanced exocrine pancreatic cancer (APC). Proc Am Soc Clin Oncol 1999;18:A1145.
27. Shulman KL, Kindler HL, Lad TE, et al: Phase II study of gemcitabine (G) and continuous intravenous infusion (CIV) 5-fluorouracil (5-FU) in advanced pancreatic cancer (PC): A University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2000;19:A1126.
28. Riedel C, Wein A, Wehler M, et al: High-dose 5-fluorouracil (FU) 24-h-infusion with gemcitabine (GEM): Tolerable and efficient in palliative outpatient treatment of pancreatic cancer. Proc Am Soc Clin Oncol 2000;19:A1248.
29. Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Piazza E, Pancera G, Giordani P, Giuliodori L, Pessi MA, Fusco V, Luporini G, Cellerino R, Catalano G: A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1999;80:1595-1598.
30. Berlin JD, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, Benson AB III: A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group Study (E3296). Oncology 2000;58:215-218.
31. Pastorelli D, Pedrazzoli S, Sperti C, et al: Phase II trial with gemcitabine (GEM) + 5-fluorouracil (5-FU) in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2000;19:A1110.
32. de Gusmao CBRA, Murad AM, Scalabrini-Neto AO, et al: Phase II trial of the use of gemcitabine (G) and 5-fluorouracil (5-FU) in the treatment of advanced pancreatic cancer (APC) and biliary tract (ABCT) adenocarcinoma. Proc Am Soc Clin Oncol 1998;17:A1116.
33. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-3275.
34. Crino L, Calandri C: Gemzar platinum combinations: Phase III trials in non-small cell lung cancer. Lung Cancer 2002;38(suppl 2):9-12.